• 1. An amphipathic trans-acting phosphorothioate RNA element delivers an uncharged phosphorodiamidate morpholino sequence in mdx mouse myotubes?
  H. V. Jain,D. Verthelyi,S. L. Beaucage RSC Adv., 2017,7, 42519-42528
• 2. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 3. Alternative mixtures to R-600a. Theoretical assessment and experimental energy evaluation of binary mixtures in a commercial cooler: Mélanges alternatifs au R-600a. évaluation théorique et évaluation énergétique expérimentale de mélanges binaires dans un refroidisseur commercial.
  DanielCalleja-Anta,DanielSánchez,LauraNebot-Andres,RamónCabello,RodrigoLlopis
• 4. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 5. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642

Recent Advances in the Study of Tert-Butyl 2-Hydroxy-7-Azaspiro[3.6]Decane-7-Carboxylate (CAS: 1445951-30-3)

The compound Tert-Butyl 2-Hydroxy-7-Azaspiro[3.6]Decane-7-Carboxylate (CAS: 1445951-30-3) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This spirocyclic structure is of particular interest due to its potential applications in drug discovery, especially in the development of novel therapeutic agents targeting central nervous system (CNS) disorders and other complex diseases. The unique azaspiro scaffold provides a versatile platform for the synthesis of biologically active molecules, making it a valuable intermediate in medicinal chemistry.

Recent studies have focused on the synthesis and optimization of Tert-Butyl 2-Hydroxy-7-Azaspiro[3.6]Decane-7-Carboxylate, with an emphasis on improving yield and purity. Advanced synthetic methodologies, including asymmetric catalysis and green chemistry approaches, have been employed to enhance the efficiency of its production. Researchers have also explored its potential as a key building block for the development of protease inhibitors and modulators of G-protein-coupled receptors (GPCRs), which are critical targets in modern drug discovery.

In a 2023 study published in the Journal of Medicinal Chemistry, the compound was evaluated for its pharmacokinetic properties and metabolic stability. The results indicated favorable oral bioavailability and low cytotoxicity, suggesting its suitability for further preclinical development. Additionally, computational modeling studies have highlighted the compound's ability to interact with specific binding sites on target proteins, providing insights into its mechanism of action and potential therapeutic applications.

Another significant advancement involves the use of Tert-Butyl 2-Hydroxy-7-Azaspiro[3.6]Decane-7-Carboxylate in the synthesis of novel small-molecule inhibitors for neurodegenerative diseases. Preliminary in vitro and in vivo studies have demonstrated its efficacy in reducing amyloid-beta aggregation, a hallmark of Alzheimer's disease. These findings underscore the compound's potential as a promising candidate for the treatment of CNS disorders.

Looking ahead, ongoing research aims to further elucidate the compound's biological activities and optimize its structural derivatives for enhanced potency and selectivity. Collaborative efforts between academic institutions and pharmaceutical companies are expected to accelerate the translation of these discoveries into clinical applications. The continued exploration of Tert-Butyl 2-Hydroxy-7-Azaspiro[3.6]Decane-7-Carboxylate and its analogs holds great promise for addressing unmet medical needs and advancing the field of chemical biology.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)